TerminatedPhase 2NCT04469699

Stereotactical Photodynamic Therapy With 5-aminolevulinic Acid (Gliolan®) in Recurrent Glioblastoma

Studying Glioblastoma

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
University Hospital Muenster
Principal Investigator
Walter Stummer, Univ.-Prof. Dr. med.
University Hospital Muenster, Klinik und Poliklinik für Neurochirurgie
Intervention
Stereotactic biopsy followed by stereotactical photodynamic therapy with 5-aminolevulinic acid(drug)
Enrollment
30 enrolled
Eligibility
18-75 years · All sexes
Timeline
20212025

Study locations (4)

Collaborators

Deutsche Krebshilfe e.V., Bonn (Germany) · photonamic GmbH & Co. KG · medac GmbH · LifePhotonic GmbH

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT04469699 on ClinicalTrials.gov

Other trials for Glioblastoma

Additional recruiting or active studies for the same condition.

See all trials for Glioblastoma

← Back to all trials